We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Product
Advertisement

Promising Target Antigens for Cell Therapy of Solid Tumors

Promising Target Antigens for Cell Therapy of Solid Tumors


Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are being conducted to evaluate the efficacy of CAR-T cells targeting FAP, GPC3, HER2, L1CAM, CEACAM5, MSLN, IL-13RA2, EpCAM, PSMA, and EGFR. Studies have demonstrated the ability of third-generation HER2 CAR-T cells to effectively eliminate glioblastoma cells, and their effectiveness can be further enhanced by combining them with PD-1 and CTLA-4 blockade. Cytokines such as IL4, TGF-β, IL-2, IL-7, IL-10, IL-12, and IL-15 are also known to play a significant role in the therapeutic effects of CAR-T therapy. 


Sino Biological provides a comprehensive range of reagents and services to support the development of CAR-T therapies targeting solid tumors.


About Sino Biological
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
Interested in seeing more content from Sino Biological?
Discover all their latest news, webinars, products and more by clicking the link below.